Neoleukin Therapeutics (NLTX) Competitors $20.09 +0.34 (+1.72%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. EOLS, ABUS, AUTL, RLAY, UPB, IOVA, DNTH, ATAI, SAGE, and AMLXShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Evolus (EOLS), Arbutus Biopharma (ABUS), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), Upstream Bio (UPB), Iovance Biotherapeutics (IOVA), Dianthus Therapeutics (DNTH), atai Life Sciences (ATAI), Sage Therapeutics (SAGE), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Its Competitors Evolus Arbutus Biopharma Autolus Therapeutics Relay Therapeutics Upstream Bio Iovance Biotherapeutics Dianthus Therapeutics atai Life Sciences Sage Therapeutics Amylyx Pharmaceuticals Evolus (NASDAQ:EOLS) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations. Which has more risk and volatility, EOLS or NLTX? Evolus has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Do institutionals and insiders hold more shares of EOLS or NLTX? 90.7% of Evolus shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 5.9% of Evolus shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is EOLS or NLTX more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -20.40%. Neoleukin Therapeutics' return on equity of -37.22% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-20.40% -759.04% -20.14% Neoleukin Therapeutics N/A -37.22%-30.91% Which has higher valuation and earnings, EOLS or NLTX? Evolus has higher revenue and earnings than Neoleukin Therapeutics. Evolus is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M2.24-$50.42M-$0.89-10.42Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-6.46 Do analysts prefer EOLS or NLTX? Evolus currently has a consensus price target of $23.75, suggesting a potential upside of 156.20%. Given Evolus' stronger consensus rating and higher probable upside, equities research analysts clearly believe Evolus is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to EOLS or NLTX? In the previous week, Neoleukin Therapeutics had 1 more articles in the media than Evolus. MarketBeat recorded 1 mentions for Neoleukin Therapeutics and 0 mentions for Evolus. Neoleukin Therapeutics' average media sentiment score of 0.67 beat Evolus' score of 0.00 indicating that Neoleukin Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Evolus Neutral Neoleukin Therapeutics Positive SummaryEvolus beats Neoleukin Therapeutics on 9 of the 15 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$188.81M$790.76M$5.53B$9.04BDividend YieldN/A4.84%5.24%4.02%P/E Ratio-6.461.3727.5820.25Price / SalesN/A230.41417.23118.60Price / CashN/A23.4436.8958.07Price / Book1.816.298.035.67Net Income-$57.56M-$27.99M$3.18B$249.21M7 Day Performance24.32%1.94%2.91%3.28%1 Month Performance-7.29%10.03%3.72%5.56%1 Year Performance-44.16%10.92%36.04%21.13% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-44.2%$188.81MN/A-6.4690EOLSEvolus3.606 of 5 stars$9.21+0.0%$23.75+157.8%-15.7%$595.47M$266.27M-10.38170Positive NewsABUSArbutus Biopharma1.6269 of 5 stars$3.11+0.5%$5.50+77.1%+2.4%$594.70M$6.17M-7.5790AUTLAutolus Therapeutics2.5559 of 5 stars$2.21-3.3%$9.32+322.7%-32.1%$586.84M$9.01M-2.51330RLAYRelay Therapeutics2.1375 of 5 stars$3.41-1.6%$17.67+418.8%-42.3%$585.50M$10.01M-1.53330UPBUpstream BioN/A$10.89-0.8%$56.50+418.9%N/A$584.70M$2.37M0.0038IOVAIovance Biotherapeutics4.71 of 5 stars$1.72-0.3%$12.22+612.7%-76.3%$572.69M$164.07M-1.38500DNTHDianthus Therapeutics1.6041 of 5 stars$17.84-4.3%$53.00+197.2%-27.7%$572.19M$6.24M-6.1880News CoverageAnalyst ForecastAnalyst RevisionATAIatai Life Sciences2.9916 of 5 stars$2.86+30.4%$8.67+203.6%+116.8%$570.37M$310K-3.1380Analyst ForecastOptions VolumeHigh Trading VolumeSAGESage Therapeutics3.2416 of 5 stars$9.08-0.5%$8.93-1.6%-13.4%$568.90M$41.24M-1.57690AMLXAmylyx Pharmaceuticals3.5163 of 5 stars$6.33-1.2%$11.00+73.7%+255.9%$565.42M$87.37M-2.04200 Related Companies and Tools Related Companies Evolus Alternatives Arbutus Biopharma Alternatives Autolus Therapeutics Alternatives Relay Therapeutics Alternatives Upstream Bio Alternatives Iovance Biotherapeutics Alternatives Dianthus Therapeutics Alternatives atai Life Sciences Alternatives Sage Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
